In this slide show we highlight some of the top news on gynecologic cancers in 2017, including studies on surgery for cervical and ovarian cancer, the FDA approval of niraparib, and more.
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers
The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.
Jyoti S. Mayadev, MD, on Pembrolizumab/CRT FDA Approval in Cervical Cancer
The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Ixabepilone Combo Improves PFS/OS in Platinum-Resistant Ovarian Cancer
Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.
Navigating the Impact of Chemotherapy Shortages on Cancer Care and Finances
Pharmaceutical, gynecologic oncology, and physician perspectives shed light on potentially mitigating the ongoing carboplatin and cisplatin shortages’ effects on cancer care in the United States.
Nab-Sirolimus Yields Sustained Responses in Gynecologic Sarcomas
Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.
CRX100 Yields Responses, Tolerability in Platinum-Resistant Ovarian Cancer
Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.